BioMarin Pharmaceutical, Inc. (BMRN)
66.53
+0.10
(+0.15%)
USD |
NASDAQ |
Sep 04, 16:00
66.52
-0.01
(-0.02%)
After-Hours: 20:00
BioMarin Pharmaceutical Research and Development Expense (Quarterly) : 206.95M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 206.95M |
| March 31, 2026 | 178.80M |
| December 31, 2025 | 192.41M |
| September 30, 2025 | 188.52M |
| June 30, 2025 | 161.31M |
| March 31, 2025 | 158.73M |
| December 31, 2024 | 173.51M |
| September 30, 2024 | 184.90M |
| June 30, 2024 | 183.79M |
| March 31, 2024 | 204.99M |
| December 31, 2023 | 206.25M |
| September 30, 2023 | 191.31M |
| June 30, 2023 | 177.36M |
| March 31, 2023 | 171.85M |
| December 31, 2022 | 172.75M |
| September 30, 2022 | 157.83M |
| June 30, 2022 | 158.19M |
| March 31, 2022 | 160.84M |
| December 31, 2021 | 161.09M |
| September 30, 2021 | 157.87M |
| June 30, 2021 | 161.11M |
| March 31, 2021 | 148.72M |
| December 31, 2020 | 156.67M |
| September 30, 2020 | 147.05M |
| June 30, 2020 | 182.14M |
| Date | Value |
|---|---|
| March 31, 2020 | 142.26M |
| December 31, 2019 | 172.81M |
| September 30, 2019 | 172.96M |
| June 30, 2019 | 185.64M |
| March 31, 2019 | 183.59M |
| December 31, 2018 | 175.39M |
| September 30, 2018 | 161.41M |
| June 30, 2018 | 175.58M |
| March 31, 2018 | 183.95M |
| December 31, 2017 | 168.61M |
| September 30, 2017 | 154.10M |
| June 30, 2017 | 143.04M |
| March 31, 2017 | 145.00M |
| December 31, 2016 | 175.24M |
| September 30, 2016 | 160.83M |
| June 30, 2016 | 167.04M |
| March 31, 2016 | 158.79M |
| December 31, 2015 | 176.12M |
| September 30, 2015 | 158.71M |
| June 30, 2015 | 157.90M |
| March 31, 2015 | 142.07M |
| December 31, 2014 | 142.07M |
| September 30, 2014 | 125.69M |
| June 30, 2014 | 108.20M |
| March 31, 2014 | 92.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| BridgeBio Pharma, Inc. | 149.45M |
| Incyte Corp. | 497.47M |
| Ionis Pharmaceuticals, Inc. | 216.41M |